Inhalation of vasoactive intestinal peptide in pulmonary hypertension

European Respiratory Journal

Volumn 32, Issue 5, 2008, Pages 1289-1294

  Leuchte, H H ^a   Baezner, C ^a   Baumgartner, R A ^a   Bevec, D ^b   Bacher, G ^b   Neurohr, C ^a   Behr, J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b mondoBIOTECH   (Switzerland)

Author keywords

Heart failure; Hypertension; Peptides; Pulmonary; Vasodilation

Indexed keywords

CARBON DIOXIDE; OXYGEN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD GAS; BLOOD SAMPLING; CLINICAL ARTICLE; CORONARY VASCULAR RESISTANCE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART CATHETERIZATION; HEART OUTPUT; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART STROKE VOLUME; HEART VENTRICLE WORK; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG DISEASE; LUNG EMBOLISM; MALE; OXYGENATION; PARAMETER; PH MEASUREMENT; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; SINGLE DRUG DOSE; VASODILATATION; VENOUS OXYGEN TENSION;

ADULT; AEROSOLS; AGED; BLOOD PRESSURE; DRUG COMBINATIONS; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; MALE; MIDDLE AGED; OXYGEN; PHENTOLAMINE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 58849114113     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00050008     Document Type: Article

References (25)

1. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 5S-12S.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
3. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006; 114: 1883-1891.
4. Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173: 744-750.
5. Hoeper MM, Rubin LJ. Update in pulmonary hypertension 2005. Am J Respir Crit Care Med 2006; 173: 499-505.
6. Rubin LJ, Galie N. Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol 2004; 43: Suppl. 12, 89S-90S.
7. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006; 48: 1672-1681.
8. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263.
9. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-694.
10. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
11. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111: 1339-1346.
12. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600-607.
13. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004; 125: 580-586.
14. World Health Organization. Proposed International Nonproprietary Names List 78. WHO Drug Information Vol. 11. Geneva, World Health Organization, 1997; pp. 265-297.
15. Bundgaard A, Enehjelm SD, Aggestrup S. Pretreatment of exercise-induced asthma with inhaled vasoactive intestinal peptide (VIP). Eur J Respir Dis Suppl 1983; 128: 427-429.
16. Barnes PJ, Dixon CM. The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am Rev Respir Dis 1984; 130: 162-166.
17. Crimi N, Palermo F, Oliveri R, et al. Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction. J Allergy Clin Immunol 1988; 82: 617-621.
18. Altiere RJ, Kung M, Diamond L. Comparative effects of inhaled isoproterenol and vasoactive intestinal peptide on histamine-induced bronchoconstriction in human subjects. Chest 1984; 86: 153-154.
19. Anaid S, Petkov V, Baykuscheva-Gentscheva T, et al. Involvement of endothelial NO in the dilator effect of VIP on rat isolated pulmonary artery. Regul Pept 2007; 139: 102-108.
20. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
21. Cox CP, Linden J, Said SI. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides 1984; 5: 325-328.
22. Rubinstein I. Human VIP-a: an emerging biologic response modifier to treat primary pulmonary hypertension. Expert Rev Cardiovasc Ther 2005; 3: 565.
23. Frase LL, Gaffney FA, Lane LD, et al. Cardiovascular effects of vasoactive intestinal peptide in healthy subjects. Am J Cardiol 1987; 60: 1356-1361.
24. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866-1870.
25. Said SI, Hamidi SA, Dickman KG, et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007; 115: 1260-1268.